Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

UGT1A6 genotype-related pharmacokinetics of deferiprone (L1) in healthy volunteers.

British journal of clinical pharmacology - 1 Jun 2008

Limenta Lie Michael George, Jirasomprasert Totsapol, Tankanitlert Jeeranut, Svasti Saovaros, Wilairat Prapin, Chantharaksri Udom, Fucharoen Suthat, Morales Noppawan Phumala

Abstract excerpt

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: UGT1A6 has been proposed as the predominant isoform responsible for the glucuronidation of deferiprone. UGT1A6*2 allele has been associated with the altered enzyme activity. WHAT THIS STUDY ADDS: There is no statistically significant effect of UGT1A6 geno...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genotype
Share to Glucuronosyltransferase
Share to Iron

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Iron Chelating Agents

Share to Polymorphism, Genetic

Share to Pyridones

Share to Sex Factors

Share to Statistics as Topic

Source

Open in PubMed Open full text

Identifiers

PMID: 18318774
DOI: 10.1111/j.1365-2125.2008.03103.x
PMCID: PMC2485226

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-18318774-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

UGT1A6 genotype-related pharmacokinetics of deferiprone (L1) in healthy volunteers.PMID 18318774Read ↗

Deferiprone glucuronidation by human tissues and recombinant UDP glucuronosyltransferase 1A6: an in vitro investigation of genetic and splice variants.Semantic proximity Read ↗

Three most common nonsynonymous UGT1A6*2 polymorphisms (Thr181Ala, Arg184Ser and Ser7Ala) and therapeutic response to deferiprone in β-thalassemia major patients.Semantic proximity Read ↗

Role of pharmacogenetics on deferasirox AUC and efficacy.Semantic proximity Read ↗

UGT1A6 variants and deferiprone-induced ADRs: a complication-specific analysis in Iranian thalassemia patients.Semantic proximity Read ↗

Determination of deferasirox plasma concentrations: do gender, physical and genetic differences affect chelation efficacy?Semantic proximity Read ↗

ABCC2 c.-24 C>T single-nucleotide polymorphism was associated with the pharmacokinetic variability of deferasirox in Chinese subjects.Semantic proximity Read ↗

Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients.Semantic proximity Read ↗

Effect of Genetic Polymorphisms on the Pharmacokinetics of Deferasirox in Healthy Chinese Subjects and an Artificial Neural Networks Model for Pharmacokinetic Prediction.Semantic proximity Read ↗

Pharmacogenetic Study of Deferasirox, an Iron Chelating AgentSemantic proximity Read ↗

Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness.Semantic proximity Read ↗

Polymorphisms in CYP2D6 have a greater effect on variability of risperidone pharmacokinetics than gender.Semantic proximity Read ↗

MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.